Press release
Lawsuit filed for Investors who lost money with shares of GeneDx Holdings Corp. (NASDAQ: WGS)
A lawsuit was filed on behalf of investors in GeneDx Holdings Corp. (NASDAQ: WGS) shares over alleged securities laws violations.
Investors who purchased shares of GeneDx Holdings Corp. (NASDAQ: WGS) have certain options and for certain investors are short and strict deadlines running. Deadline: August 3, 2026. NASDAQ: WGS investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Stamford, CT based GeneDx Holdings Corp., a genomics company, provides genetic testing services. GeneDx Holdings Corp. (NASDAQ: WGS) reported that its annual Total Revenue rose from $305.45 million in 2024 to $427.53 million in 2025, and that Net Loss declined from $52.28 million in 2024 to $21.02 million in 2025.
On May 4, 2026, after hours, GeneDx Holdings Corp disclosed that its Q1 financial results had missed for both its exome and genome lines, and cut its 2026 guidance from $540-555 million to $475-490 million. During the related earnings call, the Company disclosed that the average reimbursement rate came in at $3,300, or $200 below expectations. It also disclosed that it had taken a goodwill impairment charge of $31.3 million as a part of the Fabric Genomics acquisition - after paying $36.5 million for the Company only a year before.
Shares of GeneDx Holdings Corp. (NASDAQ: WGS) declined from $170.87 per share on December 02, 2025, to as low as $32.21 per share on May 06, 2026.
According to the complaint the plaintiff alleges on behalf of purchasers of GeneDx Holdings Corp. (NASDAQ: WGS) common shares between April 16, 2025 and May 4, 2026, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between April 16, 2025 and May 4, 2026, the Defendants failed to disclose to investors that the Company may have misled investors about the importance of Fabric Genomics, that as a result, the Company's margins would suffer, that the company's average reimbursement rates were not as "durable" as previously disclosed, that as a result of the foregoing, the Company's gross margins would decline, and that as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.
Those who purchased shares of GeneDx Holdings Corp. (NASDAQ: WGS) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lawsuit filed for Investors who lost money with shares of GeneDx Holdings Corp. (NASDAQ: WGS) here
News-ID: 4545608 • Views: …
More Releases from Shareholders Foundation, Inc.
Investigation Alert: Investors in GeneDx Holdings Corp. (NASDAQ: WGS) should con …
An investigation was announced for current long-term investors in shares of GeneDx Holdings Corp. (NASDAQ: WGS) concerning potential breaches of fiduciary duties by certain directors and officers of GeneDx Holdings Corp.
Investors who are current long term investors in GeneDx Holdings Corp. (NASDAQ: WGS) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Alarum Technologies Ltd. (NASDAQ: ALAR) Investor Alert: Lawsuit seeks to recover …
An investor, who purchased shares of Alarum Technologies Ltd. (NASDAQ: ALAR), filed a lawsuit in the U.S. over alleged violations of Federal Securities Laws by Alarum Technologies Ltd in connection with certain allegedly false and misleading statements made between March 20, 2025 and July 2, 2026.
Investors who purchased a significant amount of shares of Alarum Technologies Ltd. (NASDAQ: ALAR) have certain options and for certain investors are short and strict…
Peabody Energy Corporation (NYSE: BTU) Investor Alert: Deadline in Lawsuit on Au …
A deadline is coming up on August 24, 2026 in the lawsuit filed for certain investors of Peabody Energy Corporation (NYSE: BTU) over alleged securities laws violations by Peabody Energy Corporation.
Investors who purchased shares of Peabody Energy Corporation (NYSE: BTU) have certain options and there are strict and short deadlines running. Deadline: August 24, 2026. Peabody Energy Corporation (NYSE: BTU) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call…
Lawsuit ALERT: Investors who lost money with Alibaba Group Holding Limited (NYSE …
An investor, who purchased shares of Alibaba Group Holding Limited (NYSE: BABA), filed a lawsuit in the U.S. over alleged violations of Federal Securities Laws by Alibaba Group Holding Limited in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Alibaba Group Holding Limited (NYSE: BABA) have certain options and for certain investors are short and strict deadlines running. Deadline: October 5, 2026. NYSE: BABA investors should…
More Releases for GeneDx
GeneDx Holdings Corp. (NASDAQ: WGS) Investor Alert: Deadline in Lawsuit on Augus …
A deadline is coming up on August 3, 2026in the lawsuit filed for certain investors of GeneDx Holdings Corp. (NASDAQ: WGS) over alleged securities laws violations by GeneDx Holdings Corp.
Investors who purchased shares of GeneDx Holdings Corp. (NASDAQ: WGS) have certain options and there are strict and short deadlines running. Deadline: August 3, 2026. GeneDx Holdings Corp. (NASDAQ: WGS) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call…
Chromosomal Microarray Market Is Going to Boom | QIAGEN • Array BioPharma • …
Coherent Market Insights has released a report titled "Chromosomal Microarray Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2026-2033", which includes market percentage records and a thorough enterprise analysis. This report looks at the market's competition, geographic distribution, and growth potential. This comprehensive report encompasses industry performance, critical success factors, risk assessment, manufacturing prerequisites, project expenses, economic analysis, anticipated return on investment (ROI), and profit margins.
➤ Get Sample Copy…
Carrier Screening Market to Witness Phenomenal Growth | Major Giants GeneDx, Pro …
Latest research study released on the Global Carrier Screening Market by HTF MI Research evaluates market size, trend, and forecast to 2032. The Carrier Screening market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analyzed study to help understand market trends, growth drivers, CAGR, opportunities and upcoming challenges and about the competitors.
Key…
Pharmacogenomics (PGx) Market Size, Trends 2031 By Key Players- Abbott Laborator …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲: According to Verified Market Reports analysis, the global Pharmacogenomics (PGx) Market size was valued at USD 16.5 Billion in 2023 and is projected to reach USD 32.1 Billion By 2031, growing at a CAGR of 9.17% during the forecast period 2024 to 2031.
The Pharmacogenomics (PGx) Market presents significant opportunities for growth driven by the increasing demand for personalized medicine and advancements in genomic technologies. Pharmacogenomics, which studies…
Brugada Syndrome Market to Witness Growth Acceleration | GeneDx, PGxHealth, GE H …
Brugada Syndrome is a rare genetic condition characterized by abnormal heart rhythms and an increased risk of sudden cardiac arrest. It primarily affects the heart's electrical system, leading to dangerous arrhythmias. Individuals with Brugada Syndrome may experience fainting spells, palpitations, or sudden cardiac death, often without warning. Diagnosis typically involves electrocardiogram (ECG) testing to detect specific patterns indicative of the syndrome. Treatment options include implantable cardioverter-defibrillators (ICDs) to prevent sudden…
Genetic Testing Market is Projected to Gain Significant Value by 2028: GeneDx, I …
The latest report on the Genetic Testing Market provides a comprehensive overview of the industry's important characteristics, including production, market growth rate, industry share, consumption value and volume, demand for specific types of products and services, and more. The publication focuses on providing a competitive advantage to industry newcomers and those who aim to enter the market in the next years. It offers information on the most recent consolidations, acquisitions,…
